BioFire Diagnostics, LLC in the news
Fast pathogen identification
Tamtam found 20 recent articles about BioFire Diagnostics, LLC.
- Syndromic Multiplex Diagnostics Industry | Analysis & Key Players
The syndromic multiplex diagnostics market is experiencing significant growth, driven by the need for rapid and comprehensive pathogen identification using single-sample testing.
- bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solu
bioMérieux introduced BIOFIRE® SPOTFIRE®, a new molecular testing system for rapid and reliable mycoplasma detection in pharmaceutical manufacturing quality control.
- Clinical comparison of the BIOFIRE Joint Infection Panel using synovial fluid and tissue biopsy samples
This study evaluates the BIOFIRE Joint Infection Panel's diagnostic yield for bone and joint infections using synovial fluid and tissue biopsy samples, demonstrating improved pathogen detection, especially in polymicrobial cases, compared to traditional culture methods.
- Recent Developments in COVID-19 Diagnostic Testing
The FDA is streamlining COVID-19 diagnostic test development and approval, with many companies, including BioFire Diagnostics, securing Emergency Use Authorizations for various testing methods.
- Rapid Diagnostics to Combat Antimicrobial Resistance
NIAID supports the development of rapid diagnostics, including BioFire Diagnostics' FilmArray, to combat antimicrobial resistance by quickly identifying pathogens and informing treatment.
- Biofire Spotfire R/ST Panel Gets 510(k) Clearance, CLIA-waiver Approval
BioFire Diagnostics's Biofire Spotfire R/ST Panel received FDA 510(k) clearance and CLIA waiver for rapid detection of respiratory and sore throat pathogens.
- FDA Clears Biofire Spotfire Respiratory/Sore Throat Panel Mini
BioFire Diagnostics received FDA clearance for a 15-minute PCR test panel targeting five common respiratory and sore throat pathogens.
- First Movers in Molecular Detection: Case Comparison on Harnessing Research and Development, Industry, and Entrepreneurship
BioFire Diagnostics, LLC, and Mammoth Biosciences are highlighted as "first mover" companies in molecular detection, showcasing their innovation in qPCR and CRISPR technologies and their effective response to market opportunities like the COVID-19 pandemic.
- Proposal for antimicrobial therapy stewardship of lower respiratory tract infection in mechanically-ventilated patients based upon the Biofire® Filmarray® Pneumonia Plus panel results
Researchers developed a clinical algorithm using multiplex PCR testing to enable rapid antibiotic adjustment for patients with ventilator-associated lung infections.
- A four specimen-pooling scheme reliably detects SARS-CoV-2 and influenza viruses using the BioFire FilmArray Respiratory Panel 2.1
A study shows that a four-specimen pooling method can reliably detect SARS-CoV-2 and influenza viruses using the BioFire FilmArray Respiratory Panel 2.1.
- USAMMDA Announces FDA 510 (k) Clearance of Rapid Diagnostic Test for COVID-19
BioFire Defense received FDA 510(k) clearance for its COVID-19 Test 2, a rapid diagnostic for SARS-CoV-2 using the BioFire FilmArray instrument.
- FDA’s 1st full OK to BioFire’s COVID-19 test clears shorter path for others
BioFire Diagnostics secured the first full FDA marketing authorization for a multiplex COVID-19 and respiratory pathogen test, enabling its continued sale post-public health emergency and creating a streamlined approval pathway for other companies.
- bioMérieux to Acquire BioFire
bioMérieux is acquiring BioFire Diagnostics to expand its molecular biology offerings with the FilmArray system for infectious disease diagnosis.
- BioFire Defense Gets Fast-Track Authorization for FilmArray Ebola Test
The FDA has issued an emergency use authorization for a one-hour FilmArray ebola diagnostic test developed by BioFire Defense.
- FDA Approves FilmArray Respiratory Panel from BioFire
BioFire Diagnostics Inc. has received FDA clearance for an updated FilmArray Respiratory Panel with improved adenovirus detection.
- U.S. Department of Labor Reaches Agreement with Salt Lake City Diagnostics Company to Resolve Alleged Hiring Discrimination
The U.S. Department of Labor reached an agreement with BioFire Diagnostics to resolve alleged hiring discrimination against 193 applicants for manufacturing technician positions, resulting in $300,000 in back pay and 35 job offers.
- By the Numbers: USU Data Scientists Chase Respiratory Illness Outbreaks, including COVID-19
BioFire Diagnostics, LLC collaborates with Utah State University data scientists to refine a rapid disease-reporting system for respiratory illnesses, including COVID-19, by analyzing data from its BioFire Syndromic Trends system.
- A company that bought Theranos' patents is using them to sue a health startup working on coronavirus tests
Labrador Diagnostics, a company tied to Fortress Investment Group, is suing BioFire Diagnostics for patent infringement related to its FilmArray technology, which BioFire is using for COVID-19 tests.
- BioFire Opens Center for Molecular Diagnostics
BioFire Diagnostics opened its Alain Mérieux Center for Molecular Diagnostics in Salt Lake City, a nearly $100 million investment dedicated to developing its FilmArray PCR-based multiplex system for infectious disease diagnosis.
- Utah firm BioFire dedicates new building to growing its disease detection business
BioFire Diagnostics opened a new $100 million research and manufacturing facility in Salt Lake City to expand its infectious disease detection business.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like BioFire Diagnostics, LLC?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies